

(51) International Patent Classification ⁵ : C12P 21/08, C12N 15/13 A61K 39/395	A1	(11) International Publication Number: WO 92/05274 (43) International Publication Date: 2 April 1992 (02.04.92)
(21) International Application Number: PCT/GB91/01578 (22) International Filing Date: 16 September 1991 (16.09.91) (30) Priority data: 9020282.1 17 September 1990 (17.09.90) GB (71)(72) Applicants and Inventors: GORMAN, Scott, David [US/GB]; Flat 22, Abington House, Adrian Way, Long Road, Cambridge CB2 2SA (GB). CLARK, Michael, Ronald [GB/GB]; 108 York Street, Cambridge CB1 2PY (GB). COBBOLD, Stephen, Paul [GB/GB]; Lower Flat, 22 Guest Road, Cambridge CB1 2AL (GB). WALDMANN, Herman [GB/GB]; 11 Gurney Way, Cambridge CB4 2ED (GB).		(74) Agent: MERCHANT, James, Ian; Elkington and Fife, Prospect House, 8 Pembroke Road, Sevenoaks, Kent TN13 1XR (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: FRAMEWORK MUTATED ANTIBODIES AND THEIR PREPARATION (57) Abstract An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FRAMEWORK MUTATED ANTIBODIES AND THEIR PREPARATION

The present invention relates to altered antibodies and their preparation. The invention is typically applicable to the production of humanised antibodies.

5 Antibodies typically comprise two heavy chains linked together by disulphide bonds and two light chains. Each light chain is linked to a respective heavy chain by disulphide bonds. Each heavy chain has at one end a variable domain followed by a number of constant domains.
10 Each light chain has a variable domain at one end and a constant domain at its other end. The light chain variable domain is aligned with the variable domain of the heavy chain. The light chain constant domain is aligned with the first constant domain of the heavy chain. The constant
15 domains in the light and heavy chains are not involved directly in binding the antibody to antigen.

The variable domains of each pair of light and heavy chains form the antigen binding site. The domains on the light and heavy chains have the same general structure and
20 each domain comprises a framework of four regions, whose sequences are relatively conserved, connected by three complementarity determining regions (CDRs). The four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases
25 forming part of, the beta-sheet structure. The CDRs are held in close proximity by the framework regions and, with the CDRs from the other domain, contribute to the formation of the antigen binding site.

The preparation of an altered antibody in which the CDRs
30 are derived from a different species than the framework of the antibody's variable domains is disclosed in EP-A-0239400. The CDRs may be derived from a rat or mouse monoclonal antibody. The framework of the variable domains, and the constant domains, of the altered antibody
35 may be derived from a human antibody. Such a humanised

antibody elicits a negligible immune response when administered to a human compared to the immune response mounted by a human against a rat or mouse antibody.

Humanised CAMPATH-1 antibody is disclosed in EP-A-0328404.

5 We have now devised a new way of preparing an altered antibody. In contrast to previous proposals, this involves altering the framework of a variable domain rather than the CDRs. This approach has the advantages that it does not require a pre-existing cDNA encoding, for example, a human
10 framework to which to reshape and that it is technically easier than prior methodologies.

Accordingly, the present invention provides a process for the preparation of an antibody chain in which the CDRs of the variable domain of the antibody chain are derived
15 from a first mammalian species and the framework of the variable domain and, if present, the or each constant domain of the antibody chain are derived from a second different mammalian species, which process comprises:

(i) mutating the framework-encoding regions of DNA
20 encoding a variable domain of an antibody chain of the said first species such that the mutated framework-encoding regions encode the said framework derived from the said second species; and

(ii) expressing the said antibody chain utilising the
25 mutated DNA from step (i).

A variable domain of either or both chains of an antibody can therefore be altered by:

(a) determining the nucleotide and predicted amino acid sequence of a variable domain of a selected antibody chain
30 of the said first species;

(b) determining the antibody framework to which the framework of the said variable domain is to be altered;

(c) mutating the framework-encoding regions of DNA encoding the said variable domain such that the mutated

framework-encoding regions encode the framework determined upon in step (b);

(d) linking the mutated DNA obtained in step (c) to DNA encoding a constant domain of the said second species and
5 cloning the DNA into an expression vector; and

(e) introducing the expression vector into a compatible host cell and culturing the host cell under such conditions that antibody chain is expressed.

The antibody chain may be co-expressed with a
10 complementary antibody chain. At least the framework of the variable domain and the or each constant domain of the complementary chain generally are derived from the said second species also. A light chain and a heavy chain may be co-expressed. Either or both chains may have been
15 prepared by the process of the invention. Preferably the CDRs of both chains are derived from the same selected antibody. An antibody comprising both expressed chains can be recovered.

The antibody preferably has the structure of a natural
20 antibody or a fragment thereof. The antibody may therefore comprise a complete antibody, a (Fab')₂ fragment, a Fab fragment, a light chain dimer or a heavy chain. The antibody may be an IgG such as an IgG1, IgG2, IgG3 or IgG4 IgM, IgA, IgE or IgD. Alternatively, the antibody may be a
25 chimaeric antibody of the type described in WO 86/01533.

A chimaeric antibody according to WO 86/01533 comprises an antigen binding region and a non-immunoglobulin region. The antigen binding region is an antibody light chain variable domain or heavy chain variable domain. Typically,
30 the chimaeric antibody comprises both light and heavy chain variable domains. The non-immunoglobulin region is fused at its C-terminus to the antigen binding region. The non-immunoglobulin region is typically a non-immunoglobulin protein and may be an enzyme region, a region derived from
35 a protein having known binding specificity, from a protein

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.